Company Overview
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

For more information, please visit www.CorbusPharma.com and connect with the Company on Twitter, LinkedIn and Facebook.
Events
bio2018-mybio-sessionicon-session

10:00 AM–11:00 AM Jun 5, 2018 (US - Eastern)

bio2018-mybio-sessionicon-session

10:30 AM–11:30 AM Jun 6, 2018 (US - Eastern)